Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | FBP1 | P09467 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL651464 | 1.00 | AHR (0.54) | AHRCYP1A2NFE2L2HSD17B10FBP1 | |
| SCHEMBL11212004 | 0.85 | MAOB (0.42) | NFE2L2MAOBLMNAALOX5MAOA | |
| SCHEMBL11209918 | 0.85 | MAOB (0.42) | NFE2L2MAOBLMNAALOX5MAOA | |
| SCHEMBL11211999 | 0.85 | MAOB (0.42) | NFE2L2MAOBLMNAALOX5MAOA | |
| SCHEMBL1795502 | 0.82 | AHR (0.74) | AHRCYP1A2NFE2L2HSD17B10FBP1 | |
| SCHEMBL260347 | 0.82 | AHR (0.74) | AHRCYP1A2NFE2L2HSD17B10FBP1 | |
| SCHEMBL9679426 | 0.82 | AHR (0.74) | AHRCYP1A2NFE2L2HSD17B10FBP1 | |
| SCHEMBL20582895 | 0.82 | AHR (0.74) | AHRCYP1A2NFE2L2HSD17B10FBP1 | |
| SCHEMBL9679429 | 0.82 | AHR (0.74) | AHRCYP1A2NFE2L2HSD17B10FBP1 | |
| SCHEMBL699666 | 0.82 | AHR (0.74) | AHRCYP1A2NFE2L2HSD17B10FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106831363-A | The alkenes compounds of 1,1 dibromo 1 synthesize the method for interior alkynes with halo benzene derivative | 中国矿业大学 | 2017-06-13 | — | — | CN | claimed |
| CN-122010675-A | Method for synthesizing 1-bromo-2-styrene derivative by metal bromide catalysis | 杭州师范大学 | 2026-05-12 | — | — | CN | disclosed |
| CN-116969864-A | Synthesis method of aromatic sulfonyl fluoride compound | 江南大学 | 2023-10-31 | — | — | CN | disclosed |
| CN-110981786-A | 2-arylvinyl-cyclic amine derivative and preparation method and application thereof | 泰州医药城国科化物生物医药科技有限公司 | 2020-04-10 | — | — | CN | disclosed |
| CN-106631718-B | A kind of synthetic method of asymmetric conjugation diine | 安徽师范大学 | 2018-08-17 | — | — | CN | disclosed |
| CN-105859494-B | The preparation method of cis conjugated enynes | 安徽师范大学 | 2018-04-06 | — | — | CN | disclosed |
| CN-106831363-A | The alkenes compounds of 1,1 dibromo 1 synthesize the method for interior alkynes with halo benzene derivative | 中国矿业大学 | 2017-06-13 | — | — | CN | disclosed |
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| CN-106631718-A | Synthesis method of asymmetric conjugated diyne | 安徽师范大学 | 2017-05-10 | — | — | CN | disclosed |
| CN-105859494-A | Preparation method of cis-conjugated enyne | 安徽师范大学 | 2016-08-17 | — | — | CN | disclosed |
| US-20020161005-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-20020119973-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. | 2002-08-29 | — | — | US | disclosed |
| EP-1204640-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | Millennium Pharmaceuticals, Inc. (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1204664-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | Millennium Pharmaceuticals, Inc. (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1204665-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | Millennium Pharmaceuticals, Inc. (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1202985-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | Millennium Pharmaceuticals, Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001009094-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2001009137-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2001009119-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2001009138-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119973-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | CCL11, ACKR3, CXCR4 | AHR 2527/4885CYP1A2 3811/4885NFE2L2 2373/4885 |
| US-20020161005-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | CCL11, ACKR3, CXCR4 | AHR 2618/4885CYP1A2 3931/4885NFE2L2 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.